tirzepatide and chronic kidney disease Can be used to treat an obese patient with (CKD) Type 2 Diabetes Mellitus (T2DM), and what is the recommended dose? SURPASS-CVOT: Tirzepatide Significantly Reduces Major

D.Russell-JonesD.et al

We want to make sure all our patients are on a plan that is tailored to fit your weight loss journey

Although there is no established direct link between Mounjaro and altered warfarin metabolism, any medication that affects gastrointestinal function or dietary intake could indirectly influence warfarin's anticoagulant effect

1 The incidence of nausea in weight loss trials for semaglutide 2.4 mg weekly was 44% versus 16% for placebo

Food and Drug Administration (FDA) approval of oforglipron as a diabetes treatment as soon as possible. The company is already pursuing approval of orforglipron for obesity, and expects a decision from the FDA this spring